semaglutide fda changes just got FDA-approved for kidney disease. This everything., January 2025. The approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in Compounded GLP-1s: Why doctors worry

Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteine

Now, HUM is shaking things up again with their newest offering: Flatter Me Fiber GLP-1 Booster

This warning does not apply to Hashimotos thyroiditis or hypothyroidism caused by autoimmune or primary thyroid dysfunction

This is why its important to use electrolyte solutions to help maintain balance, while also keeping your body hydrated during your exercise routines

Increased thirst is not listed amongst the common adverse effects in the Summary of Product Characteristics (SmPC) approved by the MHRA, though some patients do report experiencing thirst during treatment